These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

539 related items for PubMed ID: 19917850

  • 1. Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma.
    O'Day SJ, Atkins MB, Boasberg P, Wang HJ, Thompson JA, Anderson CM, Gonzalez R, Lutzky J, Amatruda T, Hersh EM, Weber JS.
    J Clin Oncol; 2009 Dec 20; 27(36):6207-12. PubMed ID: 19917850
    [Abstract] [Full Text] [Related]

  • 2. Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy.
    O'Day SJ, Boasberg PD, Piro L, Kristedja TS, Wang HJ, Martin M, Deck R, Ames P, Shinn K, Kim H, Fournier P, Gammon G.
    Clin Cancer Res; 2002 Sep 20; 8(9):2775-81. PubMed ID: 12231516
    [Abstract] [Full Text] [Related]

  • 3. A phase II study of neoadjuvant biochemotherapy for stage III melanoma.
    Gibbs P, Anderson C, Pearlman N, LaClaire S, Becker M, Gatlin K, O'Driscoll M, Stephens J, Gonzalez R.
    Cancer; 2002 Jan 15; 94(2):470-6. PubMed ID: 11900232
    [Abstract] [Full Text] [Related]

  • 4. Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma.
    Lewis KD, Robinson WA, McCarter M, Pearlman N, O'Day SJ, Anderson C, Amatruda TT, Baron A, Zeng C, Becker M, Dollarhide S, Matijevich K, Gonzalez R.
    J Clin Oncol; 2006 Jul 01; 24(19):3157-63. PubMed ID: 16809738
    [Abstract] [Full Text] [Related]

  • 5. Rationale for intergroup trial E-3695 comparing concurrent biochemotherapy with cisplatin, vinblastine, and DTIC alone in patients with metastatic melanoma.
    Flaherty LE.
    Cancer J Sci Am; 2000 Feb 01; 6 Suppl 1():S15-20. PubMed ID: 10685653
    [Abstract] [Full Text] [Related]

  • 6. Development and results of biochemotherapy in metastatic melanoma: the University of Texas M.D. Anderson Cancer Center experience.
    Legha SS, Ring S, Eton O, Bedikian A, Plager C, Papadopoulos N.
    Cancer J Sci Am; 1997 Dec 01; 3 Suppl 1():S9-15. PubMed ID: 9457387
    [Abstract] [Full Text] [Related]

  • 7. Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival.
    Bedikian AY, Johnson MM, Warneke CL, McIntyre S, Papadopoulos N, Hwu WJ, Kim K, Hwu P.
    J Immunotoxicol; 2008 Apr 01; 5(2):201-7. PubMed ID: 18569391
    [Abstract] [Full Text] [Related]

  • 8. Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma.
    O'Day SJ, Gammon G, Boasberg PD, Martin MA, Kristedja TS, Guo M, Stern S, Edwards S, Fournier P, Weisberg M, Cannon M, Fawzy NW, Johnson TD, Essner R, Foshag LJ, Morton DL.
    J Clin Oncol; 1999 Sep 01; 17(9):2752-61. PubMed ID: 10561350
    [Abstract] [Full Text] [Related]

  • 9. Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma.
    Kim KB, Eton O, East MJ, Hodges C, Papadopoulos NE, Grimm EA, Bedikian AY.
    Cancer; 2004 Aug 01; 101(3):596-603. PubMed ID: 15274073
    [Abstract] [Full Text] [Related]

  • 10. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
    Minor DR, Moore D, Kim C, Kashani-Sabet M, Venna SS, Wang W, Boasberg P, O'Day S.
    Oncologist; 2009 Oct 01; 14(10):995-1002. PubMed ID: 19776094
    [Abstract] [Full Text] [Related]

  • 11. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha.
    Legha SS, Ring S, Bedikian A, Plager C, Eton O, Buzaid AC, Papadopoulos N.
    Ann Oncol; 1996 Oct 01; 7(8):827-35. PubMed ID: 8922197
    [Abstract] [Full Text] [Related]

  • 12. Biochemotherapy in patients with advanced head and neck mucosal melanoma.
    Bartell HL, Bedikian AY, Papadopoulos NE, Dett TK, Ballo MT, Myers JN, Hwu P, Kim KB.
    Head Neck; 2008 Dec 01; 30(12):1592-8. PubMed ID: 18798304
    [Abstract] [Full Text] [Related]

  • 13. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
    Hauschild A, Garbe C, Stolz W, Ellwanger U, Seiter S, Dummer R, Ugurel S, Sebastian G, Nashan D, Linse R, Achtelik W, Mohr P, Kaufmann R, Fey M, Ulrich J, Tilgen W.
    Br J Cancer; 2001 Apr 20; 84(8):1036-42. PubMed ID: 11308250
    [Abstract] [Full Text] [Related]

  • 14. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M, Burns LJ, Barker JN, Miller JS, Defor TE, Olujohungbe AB, Weisdorf DJ.
    Biol Blood Marrow Transplant; 2004 Jun 20; 10(6):395-404. PubMed ID: 15148493
    [Abstract] [Full Text] [Related]

  • 15. Long-term survival in metastatic melanoma patients treated with sequential biochemotherapy: report of a Phase II study.
    Neri B, Vannozzi L, Fulignati C, Pantaleo P, Pantalone D, Paoletti C, Perfetto F, Turrini M, Mazzanti R.
    Cancer Invest; 2006 Jun 20; 24(5):474-8. PubMed ID: 16939954
    [Abstract] [Full Text] [Related]

  • 16. Complete remission of brain metastases in three patients with stage IV melanoma treated with BOLD and G-CSF.
    Bottoni U, Bonaccorsi P, Devirgiliis V, Panasiti V, Borroni RG, Trasimeni G, Clerico R, Calvieri S.
    Jpn J Clin Oncol; 2005 Sep 20; 35(9):507-13. PubMed ID: 16120623
    [Abstract] [Full Text] [Related]

  • 17. Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study.
    Liu D, O'Day SJ, Yang D, Boasberg P, Milford R, Kristedja T, Groshen S, Weber J.
    Clin Cancer Res; 2005 Feb 01; 11(3):1237-46. PubMed ID: 15709194
    [Abstract] [Full Text] [Related]

  • 18. Basal level and behaviour of cytokines in a randomized outpatient trial comparing chemotherapy and biochemotherapy in metastatic melanoma.
    Guida M, Riccobon A, Biasco G, Ravaioli A, Casamassima A, Freschi A, Palma MD, Galligioni E, Nortilli R, Chiarion-Sileni V, Picozzo J, Romanini A, Nanni O, Ridolfi R, Italian Melanoma Intergroup (IMI).
    Melanoma Res; 2006 Aug 01; 16(4):317-23. PubMed ID: 16845327
    [Abstract] [Full Text] [Related]

  • 19. Complex combination biochemotherapy regimen in advanced metastatic melanoma in a non-intensive care unit: toxicity or benefit?
    Hofmann MA, Sterry W, Trefzer U.
    Jpn J Clin Oncol; 2007 Mar 01; 37(3):224-9. PubMed ID: 17472972
    [Abstract] [Full Text] [Related]

  • 20. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma.
    McDermott DF, Mier JW, Lawrence DP, van den Brink MR, Clancy MA, Rubin KM, Atkins MB.
    Clin Cancer Res; 2000 Jun 01; 6(6):2201-8. PubMed ID: 10873069
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.